Probiont Oy is developing a personalized solution for cancer therapy efficacy assessment. The organ-on-a-chip platform is purposed to enable rapid screening of cancer immunotherapeutics, for early identification of effective treatment strategies for individual patients.
- Founding year:
- Development phase:
- Funding stage:
- Website:
- Contact person info:
- Team members:
2021
Prototype
Pre-seed
–
benedek.poor(at)probiont.fi
3
Recent Comments